Engraftment SC vs IV plerixafor
| . | SC plerixafor 0.24 mg/kg (n = 38) . | IV plerixafor 0.32 mg/kg (n = 33) . |
|---|---|---|
| Infused CD34+ cell dose/kg, mean (range) | 3.5 × 106 (1.9-19.7 × 106) | 2.9 × 106 (2.0-9.7 × 106) |
| Patients achieving neutrophil engraftment by day 21, n (%) | 37 (97%) | 31 (94%) |
| Median time to neutrophil engraftment, d (range) | 10 (5-13) | 14 (11-27)*,† |
| Patients achieving platelet engraftment by day 30, n (%) | 36 (95%) | 23 (70%)† |
| Median time to platelet engraftment, d (range) | 22 (8-102) | 25 (15-219)† |
| 100% donor chimerism by day 100 | MA: 100% | MA: 94% (31/33) |
| RIC: N/A | RIC: 40% (2/5) |
| . | SC plerixafor 0.24 mg/kg (n = 38) . | IV plerixafor 0.32 mg/kg (n = 33) . |
|---|---|---|
| Infused CD34+ cell dose/kg, mean (range) | 3.5 × 106 (1.9-19.7 × 106) | 2.9 × 106 (2.0-9.7 × 106) |
| Patients achieving neutrophil engraftment by day 21, n (%) | 37 (97%) | 31 (94%) |
| Median time to neutrophil engraftment, d (range) | 10 (5-13) | 14 (11-27)*,† |
| Patients achieving platelet engraftment by day 30, n (%) | 36 (95%) | 23 (70%)† |
| Median time to platelet engraftment, d (range) | 22 (8-102) | 25 (15-219)† |
| 100% donor chimerism by day 100 | MA: 100% | MA: 94% (31/33) |
| RIC: N/A | RIC: 40% (2/5) |